JP5042041B2 - 心筋症及び心臓病を処置及び予防するための組成物及び方法 - Google Patents

心筋症及び心臓病を処置及び予防するための組成物及び方法 Download PDF

Info

Publication number
JP5042041B2
JP5042041B2 JP2007557223A JP2007557223A JP5042041B2 JP 5042041 B2 JP5042041 B2 JP 5042041B2 JP 2007557223 A JP2007557223 A JP 2007557223A JP 2007557223 A JP2007557223 A JP 2007557223A JP 5042041 B2 JP5042041 B2 JP 5042041B2
Authority
JP
Japan
Prior art keywords
composition
subject
poloxamer
dystrophin
heart failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007557223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008531598A (ja
JP2008531598A5 (enExample
Inventor
ジョセフ メッツガー
デュエイン タウンセンド
ソウイチロウ ヤスダ
ダン マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan Ann Arbor
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of JP2008531598A publication Critical patent/JP2008531598A/ja
Publication of JP2008531598A5 publication Critical patent/JP2008531598A5/ja
Application granted granted Critical
Publication of JP5042041B2 publication Critical patent/JP5042041B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2007557223A 2005-02-25 2006-02-27 心筋症及び心臓病を処置及び予防するための組成物及び方法 Expired - Fee Related JP5042041B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65657005P 2005-02-25 2005-02-25
US60/656,570 2005-02-25
PCT/US2006/006862 WO2006091941A2 (en) 2005-02-25 2006-02-27 Compositions and methods for treating and preventing cardiomyopathy and heart disease

Publications (3)

Publication Number Publication Date
JP2008531598A JP2008531598A (ja) 2008-08-14
JP2008531598A5 JP2008531598A5 (enExample) 2009-04-16
JP5042041B2 true JP5042041B2 (ja) 2012-10-03

Family

ID=36928113

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007557223A Expired - Fee Related JP5042041B2 (ja) 2005-02-25 2006-02-27 心筋症及び心臓病を処置及び予防するための組成物及び方法

Country Status (8)

Country Link
US (2) US7846426B2 (enExample)
EP (1) EP1853280B1 (enExample)
JP (1) JP5042041B2 (enExample)
AT (1) ATE546147T1 (enExample)
AU (2) AU2006216420B2 (enExample)
CA (1) CA2599219C (enExample)
ES (1) ES2380047T3 (enExample)
WO (1) WO2006091941A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5537152B2 (ja) * 2006-08-01 2014-07-02 フリクサス ファーマシューティカルズ， インコーポレイテッド 慢性進行性心不全のための処置
CA2682234A1 (en) * 2007-04-05 2008-10-16 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
US20110052490A1 (en) * 2007-11-29 2011-03-03 Plur0Med, Inc Endoscopic mucosal resectioning using purified inverse thermosensitive polymers
EP2719389B1 (en) * 2007-12-17 2016-07-06 The Regents Of The University Of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
US9867547B2 (en) 2012-11-29 2018-01-16 Siemens Healthcare Gmbh System and method to calculate cardiac characteristics
JP2016516825A (ja) * 2013-04-19 2016-06-09 シーダーズ−サイナイ メディカル センター 筋ジストロフィーの治療のためのホスホジエステラーゼ５ａ阻害物質
US20160235781A1 (en) * 2013-10-16 2016-08-18 Mast Therapeutics, Inc. Diuretic induced alterations of plasma volume
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
TWI688392B (zh) 2014-07-07 2020-03-21 美商救生筏生物科技公司 無長循環材料之泊洛沙姆組成物以及其製造方法和用途
WO2016007542A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
EP3965734A4 (en) * 2019-05-06 2022-12-14 Arshintseva, Elena Valentinovna Method for increasing cancer patient's haemoglobin level

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0576612B1 (en) * 1991-03-19 1999-12-01 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
JPH05178760A (ja) 1991-06-03 1993-07-20 Alpha Therapeutic Corp 心筋梗塞治療剤
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
US6761824B2 (en) * 2000-08-17 2004-07-13 Reeve Lorraine E Process for the fractionation of polymers
WO2002065834A2 (en) * 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol

Also Published As

Publication number Publication date
AU2006216420B2 (en) 2010-07-15
US20110044935A1 (en) 2011-02-24
EP1853280A4 (en) 2008-10-29
JP2008531598A (ja) 2008-08-14
US8580245B2 (en) 2013-11-12
EP1853280A2 (en) 2007-11-14
AU2010214636A1 (en) 2010-09-16
US7846426B2 (en) 2010-12-07
ES2380047T3 (es) 2012-05-08
EP1853280B1 (en) 2012-02-22
WO2006091941A3 (en) 2007-01-04
ATE546147T1 (de) 2012-03-15
CA2599219C (en) 2011-09-20
AU2006216420A1 (en) 2006-08-31
WO2006091941A2 (en) 2006-08-31
US20080260681A1 (en) 2008-10-23
CA2599219A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
US8580245B2 (en) Compositions and methods for treating and preventing cardiomyopathy and heart disease
US11873266B2 (en) Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke
RU2503453C2 (ru) Фармацевтические композиции, обладающие желаемой биодоступностью
US20220273660A1 (en) Mek inhibitor for treatment of stroke
RU2640023C2 (ru) Жидкий состав
US9155758B2 (en) Treatment of chronic progressive heart failure
KR20180127493A (ko) 승모판 질환으로 인한 무증상 심부전이 있는 환자에서 심장 크기의 감소 및/또는 임상적 증상 개시의 지연을 위한 피모벤단의 용도
PT2146721E (pt) Métodos de utilização de antagonistas da vasopressina com agentes quimioterapeuticos de antraciclina para reduzir a cardiotoxicidade e/ou melhorar a sobrevivência
BR112019012299A2 (pt) formulações farmacêuticas para o tratamento de glaucoma e métodos para a fabricação e uso das mesmas
EP1495756A1 (en) Severe sepsis preventive therapeutic agent
WO2018129347A1 (en) Methods for treating cardiovascular diseases
KR20170031084A (ko) 자가소화의 치료용의 조성물
AU2008287419A1 (en) Polymer therapy for the treatment of chronic microvascular diseases
US20110257202A1 (en) Therapeutic Compositions and Methods for Treating Chronic Kidney Disease Associated with a Metabolic Imbalance
JP2004002370A (ja) 重症セプシス予防治療剤
US12419863B2 (en) Pharmaceutical composition for use in treatment of hypertrophic cardiomyopathy
JP4733348B2 (ja) 心不全、他の加齢関連臓器機能不全および加齢関連障害の予防のための、ならびに寿命を延長するための、ナトリウム−水素交換阻害剤であるカリポライドとａｃｅ阻害剤との組み合わせ製剤
WO2024151866A1 (en) Formulations and methods of treatment for hypertrophic cardiomyopathy
Chow et al. Silent meningioma–a rare cause of stroke in post-cardiopulmonary bypass patients
JPWO2022080294A5 (enExample)
US20070173479A1 (en) Methods Using Sulodexide for the Treatment of Bladder Disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120426

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120608

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120705

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120710

R150 Certificate of patent or registration of utility model

Ref document number: 5042041

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150720

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees